Deregulated E2F Activity as a Cancer-Cell Specific Therapeutic Tool

Area of Science:

• Molecular Biology
• Cancer Biology
• Cell Cycle Regulation

Background:

• The retinoblastoma protein (pRB) tumor suppressor regulates cell proliferation by controlling the E2F transcription factor.
• Loss of pRB function and enhanced E2F activity are hallmarks of nearly all cancers.
• Current therapeutic strategies targeting E2F in cancer may affect normal cells due to shared mechanisms of E2F activation.

Purpose of the Study:

• To differentiate between E2F activity induced by growth stimulation and E2F activity resulting from pRB loss (deregulated E2F).
• To investigate the potential of deregulated E2F activity as a cancer-specific therapeutic target.
• To explore the unique molecular pathways activated by deregulated E2F in cancer cells.

Main Methods:

• Comparative analysis of gene promoter activation by E2F under different cellular conditions (growth stimulation vs. pRB loss).
• Examination of E2F dependency on its heterodimeric partner DP.
• Assessment of ARF promoter activity as a specific marker for deregulated E2F.

Main Results:

• Deregulated E2F, unlike growth-stimulated E2F, activates tumor suppressor genes, inducing senescence or apoptosis.
• Cancer cells tolerate deregulated E2F due to ARF-p53 pathway inactivation, making it cancer-specific.
• The ARF promoter exhibits higher cancer-cell specific activity compared to the E2F1 promoter, indicating selective activation by deregulated E2F.

Conclusions:

• Deregulated E2F activity represents a unique molecular feature of cancer cells.
• Targeting deregulated E2F offers a promising strategy for developing cancer-specific therapies.
• This approach minimizes potential harm to normal proliferating cells.